John has been covering financial markets since before the FTSE 100 existed, starting out on the Industries and Commodities team at Dun & Bradstreet, before moving on to Datastream, where he was head of the news team for several years. After a succession of management roles at Thomson Reuters he returned to front-line journalism in 2006. Prior to joining Proactive Investors he was managing editor at Sharecast.
The company's retinitis pigmentosa clinical programme benefits from orphan drug designation in both Europe and the US, as well as a fast track designation from the FDA in the US
An update on the collaboration with Moderna is planned for the first half of this year
The Affimer technology is Avacta's proprietary alternative to antibodies with wide applications in the life sciences for drug development, diagnostics and research tools
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes
"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO
Securing approval in the US for iclaprim remains the top priority for Motif Bio, the company said as it posted full-year 2018 results which saw losses narrow sharply
"We continue to execute our strategy of market entry for our Hepatitis C point of need molecular test and development of both our tuberculosis and antibiotic-induced hearing loss assays," said David Budd, the CEO of genedrive
"The share placing completed at the end of February gives the business the requisite funds for further corporate store openings and investment in sales and marketing," said CEO, Peter Shaw
Our tweaked UK take on the famous "Dogs of the Dow" strategy performed very well in its first year (to end January 2018) but pooped on the pavement in the second year
Stockpot's "AIM sustainable dividends" virtual portfolio was conceived as a way of screening out the "jam tomorrow" companies on AIM to focus on those companies capable of paying rising dividends. The last couple of months have seen almost 18 months of gains wiped out.
In another update on the "mindless momentum" mechanical investment strategy - this time on small caps worth less than £100mln - nine of the 10 stocks head for the door having failed to sustain their momentum.
After setting the IPO price at the bottom of the range failed to prevent a disastrous stock market debut for Funding Circle, the stock is beginning to recover. It's a tricky stock to value because of the alleged disruptive nature of the peer-to-peer (P2P) lending model but in the US, investors seem a lot more sceptical about...